Targeting glucose toxicity in heart cells during low oxygen conditions
Systems genomics approach to targeting glucose toxicity during pathological cardiomyocyte hypoxia
This study is looking at how heart cells cope with low oxygen levels, which can happen in heart disease and lung problems, to find new ways to help protect heart function and improve treatments for patients dealing with these issues.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11031312 on NIH RePORTER |
What this research studies
This research investigates how heart cells adapt to low oxygen levels, which can occur in conditions like heart disease and chronic lung issues. By using a functional genomics approach with heart cells derived from induced pluripotent stem cells, the study aims to identify the molecular pathways that help these cells survive under hypoxic conditions. The goal is to develop new therapeutic strategies that can protect heart function by manipulating these pathways. Patients may benefit from insights that could lead to innovative treatments for heart-related conditions caused by oxygen deficiency.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with heart diseases or conditions that cause chronic hypoxia, such as ischemic heart disease or chronic obstructive pulmonary disease.
Not a fit: Patients with non-cardiac conditions or those not experiencing issues related to oxygen deficiency may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve heart function in patients suffering from conditions related to low oxygen levels.
How similar studies have performed: Other research has shown promise in understanding metabolic adaptations in heart cells, suggesting that this approach could yield valuable insights.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Flanigan, Will Robert — University of California, San Francisco
- Study coordinator: Flanigan, Will Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.